Animal Models of Alzheimer’s Disease: Utilization of Transgenic Alzheimer’s Disease Models in Studies of Amyloid Beta Clearance by Tarja Malm et al.
COGNITIVE FUNCTION AND AGING (DAVE MORGAN, SECTION EDITOR)
Animal Models of Alzheimer’s Disease: Utilization of Transgenic
Alzheimer’s Disease Models in Studies of Amyloid Beta Clearance
Tarja Malm & Johanna Magga & Jari Koistinaho
Published online: 19 January 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Glial cells in Alzheimer’s disease (AD) have been
shown to be capable of clearing or at least restricting the
accumulation of toxic amyloid beta (Aβ) deposits. Recently,
bone marrow (BM)–derived monocytic cells have been
recognized in experimental studies to be superior in their
phagocytic properties when compared to their brain endog-
enous counterparts. In human AD, BM-derived monocytic
cells may have deficiencies in their capacity to restrict
plaque growth. Therefore, enhancement of phagocytic prop-
erties of cells of monocyte origin, both brain endogenous
microglia and BM-derived monocytic cells, offers an attrac-
tive therapeutic approach to fight off AD. Transgenic mouse
models with aberrant Aβ deposition offer a valuable tool for
discovery of novel pathways to facilitate cell-mediated Aβ
uptake. This article reviews the most recent findings on the
phagocytic capacity of cells with monocytic origin in various
transgenic AD models and describes the methods to study
phagocytic activity of these cells.
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Introduction
Microglia and bone marrow (BM)–derived monocytic cells
have been implicated in Alzheimer’s disease (AD) patho-
genesis. The role of microglia in the development of AD has
for long been under debate. As AD progresses, the magni-
tude of proinflammatory microglia-secreted cytokines
increases, contributing to the vicious cycle of inflammation
and following neuronal damage. In addition, some evidence
suggests that microglia may actually promote Aβ deposi-
tion. On the other hand, whereas microglial phagocytosis of
Aβ in vivo may be rather limited, microglia in vitro are
efficient Aβ phagocytes. A subpopulation of brain mono-
cytic cells enters the brain from the circulation upon brain
damage. Infiltration of BM-derived cells is very limited in
healthy brain and in AD transgenic mice [1, 2••] but this
infiltration is increased upon injury associated with blood–
brain barrier (BBB) disruption, and infiltrated monocytic
cells have been detected in brains of AD patients who quite
often suffer from comorbidities such as small cerebral
infarcts [3]. BM-derived cells have been shown to be supe-
rior in phagocytosing and clearing Aβ in several different
models developed to assess phagocytic activity [4–7]. AD
transgenic mice with aberrant Aβ accumulation have been
the major cornerstone in studies revealing novel pathways to
enhance Aβ clearance. This review article describes the
most recent findings on the phenotype of phagocytic cells
across different currently available transgenic AD models.
In addition, development of methods for assessing the Aβ
phagocytic properties is discussed.
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Alzheimer’s Disease Animal Models
AD research was clearly boosted by the development of
transgenic mouse models, and to date, the availability of
such models is ample. The obtained pathology of AD mice
depends on the transgene, promoter, and mutation of choice;
the integration site; and the achieved expression level of the
transgene. Human amyloid precursor protein (hAPP) in
different length, either 695, 751, or 770 amino acids, have
been used as transgenes with several mutations and with
either neuron-specific platelet-derived growth factor and
Thy-1 promoters or nonneuronal hamster PrP promoter.
The onset and severity of Aβ pathology has been indicated
to depend on achieved Aβ 1–42 levels, with the mutations in
APP augmenting the pathology (reviewed in [8]). Whereas
mutated APP isoforms seem to be sufficient to cause Aβ
deposition, presenilin (PS) 1 or 2 alone are unable to result
in any detectable lesions despite the fact that elevation in Aβ
levels is observed. Overexpression of mutated PS together
with mutated hAPP isoforms aggravates the progression of
Aβ pathology with earlier appearance of the plaques. In
addition to the APP- and PS-based transgenic mice, transgenic
mice carrying mutated tau also have been developed [9].
Overexpression of tau alone is not sufficient to result in
plaques, but, together with APP and PS, recapitulates both
neurofibrillary tangles and plaques.
Despite the transgene expressed, none of the currently
available transgenic mouse models capture the full human
AD pathology. However, they are suitable for studies of Aβ
phagocytosis due to the facts that
(1) similar to human brain, Aβ deposition increases with
aging;
(2) Aβ in mouse models occurs in similar form as in
human AD brain; compared to human cases, the de-
posited Aβ in AD transgenic mice is similar in size,
and stains with Congo red and Thioflavin S and also
can be found around the vasculature as amyloid
angiopathy;
(3) plaques are recognized by glial cells which are recruited
around the deposits; and
(4) brain levels of Aβ in these models correlate, at least to
some extent, with the severity of cognitive impairment
(nicely reviewed by Duyckaerts et al. [8]).
Microglial Phenotype in Alzheimer’s Disease Models
Microglia are the main immunological effector cells with
phagocytic properties in the brain. The origin of microglia
has long been suggested to lay on the hematopoietic progen-
itor cells; however, recent reports show that microglia derive
from primitive myeloid progenitors at early embryonic life but
later are maintained with minimal contribution of hematopoi-
etic cells of peripheral origin [10, 11]. Microglia are difficult
to be distinguished from other myeloid subsets, however, very
recently microglia was reported to express fractalkine receptor
CX3CR1, but not the chemokine receptor CCR2, from
embryonic stage throughout life [11]. The phenotype of
microglia had long been referred to as being either active or
resting; however, it now is widely recognized that microglia
display various forms of activation states and are never rest-
ing, but rather constitutively survey the brain parenchyma for
pathogens. Microglial phenotypes are being categorized into
M1 and M2; the latter also referred to alternative activation.
M2 activation state has been further subcategorized into M2a,
M2b, and M2c, but most likely any category is not able to
fully capture the microglial function because microglia may
have unique activation properties depending on the type of
stimuli [12].
Microglia in AD mice have been proposed to exert
proinflammatory phenotype. Exogenously added Aβ has
been shown to promote the production of several proin-
flammatory mediators, such as interleukin (IL)-1β, IL-6,
tumor necrosis factor (TNF)–α, macrophage inflamma-
tory protein-1 (MIP-1), Aβ degrading enzymes, prosta-
noids, complement proteins, and free radicals [13]. On
the other hand, microglia recognize and respond differ-
ently even to different forms of Aβ. Oligomeric, the
more toxic form of Aβ, has been shown to cause M1
shift in microglial phenotype compared to fibrillar form
of the peptide [14]. In addition, preexisting activation
state achieved with anti-inflammatory cytokines reduces
microglial reactivity to Aβ [14].
Several proinflammatory cytokines, such as IL-6, TNF-
α, and IL-1β, have been shown to be increased In brains of
human AD patients [13, 15]. The situation is similar in AD
transgenic mouse models. The overall levels of proinflamma-
tory cytokines of microglial secretion seem to be upregulated,
indicating a classical, cytotoxic activity of microglia, though
detected cytokines and the time point of their upregulation
may vary from model to model. Several studies have assessed
microglial cytokine secretion [16–18] from whole brain
homogenates or brain total microglia, but because other brain
cells are equally capable in secreting the same cytokines as
microglia and microglia may differ in their cytokine secretion
depending on their surroundings, more cell-specific studies
are clearly needed. Aging also may cause a shift in microglial
phenotype [19]. Table 1 lists the cytokine expression profile of
some commonly used AD transgenic models. In most models,
Aβ accumulation precedes the upregulation of cytokines.
Indeed, Aβ-laden milieu causes a shift in microglial pheno-
type, which may depend on not only the total brain Aβ
pathology but also the microenvironment the microglial cell
encounters [19, 20]. Bolmont et al. [20] showed that microglia
in the vicinity of plaques are actively taking up additionally
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injected Aβ dye in contrast to microglia further away from the
plaques and in brains of wild-type controls, suggesting a
polarized surrounding-dependent activation and phagocytic
capacity of microglia in AD mouse brain. Also, neurotrans-
mitters and neuropeptides may modulate microglial activity
and Aβ phagocytosis [21, 22]. A deeper knowledge of the
microglial activation properties is urgently needed to fully
understand how microglial activation status could be adjusted
toward more efficient phagocytosis without risking other,
important properties of microglia in AD brain.
Bone Marrow–derived Monocytic Cells in Alzheimer’s
Disease Models
Several studies have failed to show efficient microglial in
vivo Aβ phagocytosis without additional stimulus, yet in-
creasing evidence shows that peripheral macrophages and
monocytic cells are competent phagocytes. These cells have
their origin in the BM, where they develop from hemato-
poietic stem cells (HSC). Upon stimuli, monocytic cells are
released from BM into the circulation. Monocytes in the
bloodstream are rather short-living and infiltrate into the target
tissues followed by cytokine and chemokine secretion. The
Ly6C+CCR2+ monocytes have been shown to be the direct
infiltrating precursors of BM-derived microglia in the brain,
with the chemokine CCL2 being the major contributor in
mediating the infiltration. Infiltrating COX-2 immunoreactive
monocytic cells containing intracellular Aβ also have been
found in human AD brain [23]. Similar to brain microglia,
BM-derived cells also have been categorized based on their
activation state and expression of cell surface molecules.
Roughly, proinflammatory Ly6C+ monocytes are recruited in
inflamed tissue mediated by CCL2-CCR2 interaction, where-
as Ly6C– monocytes are thought to be recruited at the resolv-
ing phase of the insult mediated by CX3CR1 and take part in
wound repair and tissue remodeling processes [24, 25] .
Whether or not microglia phagocytose Aβ in AD brain or
contribute to Aβ accumulation is not yet clear; however,
several lines of evidence suggest that BM monocytic cells
are efficient phagocytes in vitro and in vivo [26–28]. In
addition, there is evidence that monocytes in patients with
AD have deficient capacity to phagocytose Aβ [29].
Although Aβ pathology itself may not be sufficient in
increasing the infiltration of BM-derived monocytic cells
in AD transgenic mouse brain [2••], AD patients frequently
Table 1 Microglial cytokine expression profiles in some Alzheimer’s disease mouse models
Study AD mouse model Development of
Aβ pathology
Detection method Cytokine expression profile
Masoumi et al. [80] APPswe/PS1dE9 4 months IHC TNF-α ↑ starting at age 8 mo and
IL-1β, IL-6, and MCP-1 ↑ starting
at age 10 mo
Hoozemans et al. [15] APPswe/PS1dE9 4 months Isolated microglia; qPCR SRA, CD36, RAGE, insulysin,
neprilysin, and
MMP-9 ↓; IL-1β and TNF-α↑
starting at age 8 mo
Farfara et al. [81] Tg2576 9–11 months IHC; in situ hybridization IFN-γ and IL-12 ↑ and IL-4 ↓ starting
at age 9 mo
Jankowsky et al. [16] APPswe; APP/PS1 11 months in APPswe;
10 weeks in APP/PS1
Organotypic slice cultures;
multiplex cytokine assay
IL-1α, TNF-α, GM-CSF, and IL-6 ↑
at age 15 mo in both models.
APP/PS1 brain slices produced
significantly more IL-12p40, IL-1β,
IL-1α, TNF-α, GM-CSF, and IL-6
compared to APPswe brain slices.
Cytokine levels correlated with brain
Aβ in both models
Hickman et al. [17] PS1(M146L) x
APP751sl
3–4 months Brain homogenates; qPCR TNFα, iNOS, IL-1β, FASL, TRAIL,
nox1, and Cox2 ↑ at age 18 mo.
IL-1β ↑ at age 12 mo
Hickman et al. [17] PS1(M146L) x
APP751sl
3–4 months IHC Microglia in the near vicinity of Aβ
plaques were shown to adopt an
incomplete alternative activation
state characterized by elevation of
YM-1 and absence of TNF-α and
iNOS at age 18 mo
Aβ beta amyloid; AD Alzheimer’s disease; FASL Fas ligand; GM-CSF granulocyte-macrophage colony-stimulating factor; IFN-γ interferon-
gamma; IHC immunohistochemistry; IL interleukin; iNOS inducible nitric oxide synthase; MCP monocyte chemotactic protein-1; MMP-9 matrix
metalloproteinase 9; qPCR quantitative polymerase chain reaction ; RAGE receptor for advanced glycation endproducts; SRA scavenger receptor A;
TNF-α tumor necrosis factor alpha; TRAIL TNF-related apoptosis-inducing ligand
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suffer from comorbidities such as cerebral infarcts, which
are associated with BBB damage. Therefore, it is likely that
BM-derived monocytic cell infiltration occurs in human
AD. In addition, CD11b+ myeloid cells have been shown
to infiltrate into AD transgenic mouse brain when infused
into the bloodstream [30•]. Even without parenchymal infil-
tration, BM-derived cells may have an important function as
Aβ phagocytizing perivascular macrophages, the absence of
which was associated with increased cerebral amyloid angiop-
athy (CAA) and mortality in CCR2-deficient AD mice [2••].
Aβ Phagocytosis and Degradation in Alzheimer’s
Disease
In familial cases of AD, imbalance in the production and
clearance of Aβ leads to harmful responses to specific Aβ
species in neurons and glia, Aβ accumulation, and, eventu-
ally, progressive neurodegeneration [31]. Even small chron-
ic deficits in the mechanisms of Aβ reduction may lead to
aberrant Aβ accumulation. Dysfunctions in Aβ clearance
by microglia or BM-derived monocytic cells in the brain
parenchyma, Aβ egress from brain to blood, or Aβ clearance
by perivascular macrophages and peripheral blood monocytes
may contribute to increased Aβ burden. Depending on the site
of Aβ accumulation, it can be referred to as parenchymal Aβ
deposition or CAA. Although these conditions have different
appearances and possibly altered disease severity, they prob-
ably carry similar pathological mechanisms, which also may
work in parallel.
The role of microglia in the regulation of Aβ levels in
AD has been under intensive investigation. Depending on
conditions, glial cells may have a role in AD by potentially
contributing to increased Aβ burden [32]. However, microglia
as brain mononuclear phagocytes have been shown to partic-
ipate in Aβ reduction with multiple mechanisms. Microglia
are able to secrete various proteases such as neprilysin,
insulin-degrading enzyme, angiotensin-converting enzyme,
cathepsin B, cystatin C, and matrix metalloproteases (MMPs),
which may degrade Aβ, among other biologically active
peptides [31]. After stating this, in this context we concentrate
on Aβ removal by phagocytic mechanisms by myeloid cells
including microglia.
Microglia take up soluble Aβ species through nonsatur-
able fluid phase macropinocytosis and traffic them into the
late endosomes and lysosomes for degradation [33]. Oligo-
meric Aβ uptake by microglia involves recognition of Aβ
by scavenger receptors, followed by Aβ internalization,
trafficking to lysosomes, and degradation by lysosomal
proteases including cathepsin B [34]. Fibrillar Aβ is recog-
nized by cell surface innate immune receptors, including
scavenger receptors and toll-like receptors (TLR), and taken
up by receptor-mediated phagocytosis or endocytosis
[35–37] . Also, some other receptors have been linked to
fibrillar Aβ phagocytosis, such as a Dap12-associated re-
ceptor called signal regulatory protein-β1 (SIRPβ1) [38] or
triggering receptor expressed on myeloid cells (TREM2)
[39], low density lipoprotein (LDL) receptor, and apolipo-
protein E (apoE), as reviewed by Bu [40]. Specifically,
macrophages from ApoE2 mice are more efficient in
degrading Aβ than ApoE3 macrophages, which in turn are
better phagocytes than ApoE4 macrophages [41•].
Low activity of lysosomal enzymes in microglia in com-
parison tomacrophages may account for the limitedmicroglial
degradation of Aβ [6]. The question remains as to what extent
microglia are able to degrade fibrillar Aβ and whether mono-
cytes derived from the periphery would outweigh parenchy-
mal microglia in Aβ clearance in vivo. In addition to limited
phagocytosis, microglial capacity for efficient Aβ degradation
also may be limited [42]. Even though microglia in the AD
brain and similarly in AD mouse brain can take up Aβ, their
Aβ removal capacity is not sufficient to prevent the accumu-
lation of plaques without any intervention. Thus, interventions
aiming at facilitating the uptake and degradation of Aβ by
microglial cell are an attractive therapeutic approach.
In Vitro Methods in Studying Aβ Phagocytosis
in Alzheimer’s Disease Models
The phagocytosis of Aβ is in its simplest form studied by
incubating cells with recombinant Aβ peptides and quanti-
fying uptake and degradation of Aβ peptide from the cells.
The fact that Aβ peptides are prone to aggregation, the
origin of Aβ preparation, and the way Aβ is solubilized
may obviously cause a lot of variation in the outcome of the
form of Aβ that is finally applied on the cells. This may
explain high variation in the responses to Aβ detected
between different cell culture studies. There are many sec-
ondary cell lines utilized as models of inflammatory cells,
such as immortalized microglia cell lines BV-2, N9,
MMGT12, and C8-B4 from mouse origin; HAPI from rat
origin; and HMO6 and CHME3 from human origin, as well
as macrophage cell line RAW264.7 of mouse origin and
monocyte cell line THP-1 of human origin. BV-2 microglia
is one of the most utilized cell lines in Aβ phagocytosis
studies in vitro [43, 44].
Secondary cells have many similarities but also several
differences to primary microglia [43–45], which are one step
closer to native microglia. Primary microglia can be
obtained from neonatal or adult rodents [46–48] as well as
postmortem human brain [49]. Neonatal microglia, a model
widely used to study microglia function, actually consist of
subpopulations of cells displaying partially different func-
tions [28, 50, 51]. Neonatal microglia also may have imma-
ture responses to inflammatory stimulus compared to adult
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microglia, which have decline in proteasomal function and
reduced Aβ phagocytosis [46, 52]. Also, microglia
obtained from aged animals show altered responses to
inflammation and decreased Aβ uptake and phagocyto-
sis in comparison to microglia isolated from young
adult animals [48]. Aged animals also have reduced
expression of Aβ-binding receptors and Aβ-degrading
enzymes [17]. Primary monocytes can be obtained from
mouse BM or human peripheral blood, or from HSC by
differentiation with macrophage colony–stimulating factor
(MCSF) [28, 53]. Macrophages can be collected from mouse
peritoneum after induced inflammatory stimulus or by spon-
taneous or MCSF-induced differentiation of primary mono-
cytes in vitro [6, 28, 29, 41•, 54].
For the simplest Aβ uptake studies, cells are incu-
bated with a fluorochrome-conjugated Aβ, which can be
tracked inside the cells using fluorescent microscopy or
quantified by flow cytometry [28, 29, 33, 41•]. To study
degradation of internalized Aβ, quantification of remain-
ing Aβ protein levels within the cells is recommended
instead of fluorescence signal to ensure that the readout
is true Aβ clearance and not just fadeout of the fluoro-
chrome. Phagocytosis in general also can be studied by
feeding the cells with fluorescent beads or latex beads;
however this is a nonspecific assay for overall phago-
cytic activity.
Ex Vivo Methods in Studying Aβ Phagocytosis
in Alzheimer’s Disease Models
To expose the cells into a more authentic environment for
Aβ phagocytosis, the cells may be applied on top of brain
sections prepared from aged transgenic AD mice containing
native Aβ deposits [28, 41•, 55, 56]. The reduction in Aβ
burden can be determined by immunohistochemical Aβ
staining as well as quantification of protein levels. The
sections also may be obtained from postmortem samples
from AD patients as a more suitable model for studying
Aβ phagocytosis when cells of human origin are investigated.
The ex vivo Aβ phagocytosis assay is superior to Aβ uptake
assay in regard to the exposure of cells into native AD brain
conditions, which may modulate the cell phenotype mimick-
ing the in vivo situation. Preferably, cells of various origin and
alternative methods should be combined when studying the
mechanisms of Aβ phagocytosis.
In Vivo Methods in Studying Aβ Phagocytosis
in Alzheimer’s Disease Models
Finally, the most relevant model for Aβ phagocytosis is to
utilize transgenic mouse models of AD. To study the role of
specific factors involved in the Aβ clearance, transgenic AD
mice have been crossbred with mouse strains lacking or
overexpressing certain protein products. Because knocking
out specific genes may have developmental consequences
or, on the other hand, the gene function may be compensated
by other factors, it is an advantage to utilize conditional trans-
gene technology. With this technology, the expression of a
particular gene is conditional to a specific stimulus and can be
switched “on” or “off” as desired. This has been utilized with
AD models in order to ablate a certain type of cell to study
their contribution to AD pathology [4, 57, 58].
First studies showing the infiltration of peripheral
myeloid cells in AD mouse brain have taken advantage
of the chimeric mouse model. In this model, recipient
mice are irradiated and their blood cell production is
reconstituted by transplantation of either purified HSC
or crude leukocyte population including HSC. Donor
mice expressing a reporter gene, such as green fluores-
cent protein, have been utilized to track the peripheral
derived cells from the brain. Although the method is
widely used [4, 26, 59], the irradiation in the chimeric
model has been legitimately criticized for causing pre-
conditioning leading to increased permeability of BBB
and excessive peripheral cell infiltration into the brain paren-
chyma [1, 2••]. Other approaches have been to transplant the
cells to naive mouse circulation or locally into the brain to
study their Aβ phagocytosis [28, 30•, 60].
Aβ burden in the brain can be quantified with im-
munohistochemical staining for total Aβ or with Congo
red staining for fibrillar Aβ plaques. The levels of
soluble and insoluble Aβ species may be determined
from the brain and blood with enzyme-linked immuno-
sorbent assay. Because AD pathology and Aβ deposi-
tion occur in transgenic mice within months and may
require as long as 1–2 years to fully develop, there is a
demand for methods that would allow monitoring the
Aβ burden in longitudinal studies. Recent progresses in
neuroimaging techniques enable this monitoring in vivo.
Positron emission tomography with Aβ tracers can be
utilized to directly visualize Aβ in vivo [61]. Also, the
development of magnetic resonance imaging techniques
has led to promising results in visualization of Aβ
deposits [62]. Aβ deposition and interaction with cells
can be monitored in brain in vivo utilizing multiphoton
microscopy [20, 63, 64••]. In general, alterations in Aβ
burden can be monitored in parallel with behavioral
studies to link it to possible changes in memory deficits
and anxiety. However, the Aβ burden and learning
deficits do not necessarily correlate because other mecha-
nisms or specific forms of Aβ may engage to these processes
[65–68] . The findings on the mechanisms of Aβ phagocyto-
sis in AD models will be discussed in more detail in the next
paragraph.
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Table 2 Role of specific myeloid cells or factors regulating myeloid cell migration or activity affiliated to Aβ clearance in the animal
models of AD
Study Cells Model Effect on Aβ burden
Mildner et al. [2••] BM CCR2+ cells CCR2−/−BM cell chimera in
APPswe/PS1 and Tg2576
mice
Irradiation preconditioning and CCR2 expression
in BM cells are required for their brain
engraftment. Peripheral macrophages rather than
parenchymal microglia modulate Aβ deposition
in AD mice
El Khoury et al. [5] CCR2 CCR2−/−mice crossed with
Tg2576 mice
Absence of CCR2 impairs microglia accumulation
and increases Aβ levels and mortality in AD
mice
Magga et al. [28] BM CD11b+ cells Adoptive transfer of neprilysin-
transfected BM CD11b+ cells
into APP/PS1mice
BM CD11b+ cells home to AD mouse brain after
adoptive transfer. Injection of CD11b+ cells
expressing secreted form of neprilysin is
associated with reduced Aβ burden
Koistinaho
et al. [56]
Microglia/CD11b+ cells CD11b+ cell ablation in APPPS1
and APP23 mice
Nearly complete ablation of CD11b+ cells did not
alter Aβ levels in AD mice within the
observation period of 4 weeks
Ruan et al. [82] CD11c+ TGF-β+ cells Dominant negative TGF-β in
CD11c+ cells in Tg2576 and
APPswe/PS1dE9 mice
TGF-β deficiency in CD11c+ reduced
parenchymal and vascular Aβ burden involving
infiltration of peripheral macrophages
Abbas et al. [83] CD45 CD45−/−crossed with
APPswe/PS1dE9 mice
CD45 deficiency promotes proinflammatory
microglial activation, reduces their phagocytic
activity, and increases soluble and insoluble Aβ
levels
Town et al. [84] Myeloid differentiation
factor 88
MyD88−/−BM cell chimera in
TgCRND8 and APPswe/PS1dE9
mice
MyD88 deletion in BM cells attenuates
neuroinflammation, enhances Aβ phagocytosis,
and reduces Aβ burden
Zhu et al. [85] and
Hao et al. [86]
CX3CR1 CX3CR1−/−crossed with APPPS1
mice
Absence of CX3CR1 leads to altered
inflammation, enhancement of microglia Aβ
phagocytosis, and reduction of Aβ burden
Lee et al. [87] CD14 CD14−/−crossed with APPswe/PS1dE9 mice TLR co-receptor CD14 deficiency alters
microglia activation and reduces microgliosis
and Aβ burden
Liu et al. [88] TLR4 TLR4 mutation mice crossed with
APPswe/PS1dE9 mice
TLR mutation decreases microglia activation and
increases Aβ deposition in early AD possibly
involving reduced Aβ clearance
Reed-Geaghan
et al. [89]
TLR9 ligand TLR9 ligand CpG injection (i.c.v)
into Tg2576 mice
TLR9 ligand CpG reduces Aβ burden and
increases microglial production of degrading
enzymes and reduction of Aβ
Song et al. [90] EP2 EP2−/−BM cell chimera in APPswe/
PS1dE9 mice
EP2 deletion in BM cells reduces Aβ burden
Doi et al. [91] and
Keene et al. [92]
Liver X receptor LXR agonist p.o. into APP23 mice,
LXR−/−crossed with APPswe/PS1dE9
mice
LXR agonist reduces Aβ burden in AD mice on
high-fat diet. Astrocytic LXR activation and the
release of ApoE are involved in microglial Aβ
phagocytosis
Terwel et al. [93] Complement
factor C3
C3−/−crossed with APP mice Absence of C3 drives microglia into M2
alternative activation phenotype and increases
Aβ burden
Fitz et al. [94] IL-6 AAV1-induced IL-6 overexpression in
brain of TgCRND8 and Tg2576 mice
Overexpression of IL-6 leads to massive gliosis,
and attenuates Aβ deposition by enhanced
microglia activation and possibly by increased
Aβ phagocytosis
Maier et al. [95] IL-1β Overexpression of IL-1β in brain of
APPswe/PS1dE9 mice
Sustained overexpression of IL-1β enhances
microglia activation and reduces Aβ burden
Chakrabarty
et al. [96]
MCSF Weekly i.p. injections of MCSF into
APPswe/PS1
MCSF increases microgliosis and BM cell
infiltration and reduces Aβ burden by
phagocytosis
Aβ beta amyloid; AAV adeno associated virus; AD Alzheimer’s disease; apoE apolipoprotein E; BM bone marrow; EP2 prostaglandin E2 receptor
subtype 2; i.c.v. intracerebroventricular; IL interleukin; i.p. intraperitoneal; LXR liver x receptor; MCSF macrocyte colony–stimulating factor; p.o.
per oral; TGF-β+ transforming growth factor beta; TLR9 toll-like receptor 9
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Mechanisms of Aβ Phagocytosis in Myeloid Cells
in Alzheimer’s Disease Models
Microglia-mediated clearance of Aβ in vivo may be rather
limited, but it can be enhanced by opsonization of Aβ
deposits obtained with active or passive immunotherapy.
Enhanced Aβ clearance in turn associates with alleviation
of AD-related neuropathological alterations (reviewed in
[69]). The Aβ-antibody complex is identifiedwith Fc receptors
present in immune cells, including microglia and macrophages
subsequently leading to Fc receptor–mediated phagocytosis
(reviewed in [70]). However, microglia-mediated Aβ phago-
cytosis does not explain all the beneficial effects of immuniza-
tion because other mechanisms, such as altered Aβ
fibrillization in brain parenchyma or enhanced brain to blood
efflux of Aβ also may occur (reviewed in [69]).
Although the immunotherapy treatment for AD is promis-
ing, it is hindered by severe adverse effects such as brain
microhemorrhages observed in animal studies and encephali-
tis observed in clinical trials after passive and active immuni-
zation, respectively, as reviewed in [69]. It has been reported
that macrophages laden with Aβ may get trapped to endothe-
lial layer, inhibiting the monocyte emigration and Aβ export
across BBB [53], possibly partly explaining the increased
occurrence of hemorrhages. There are naturally occurring
autoantibodies to Aβ in plasma and cerebrospinal fluid that
exist in both healthy individuals as well as in AD patients
although their levels may be decreased in advanced AD as
well as within normal aging [71, 72] . Because these autoanti-
bodies promote microglia-mediated uptake and clearance of
Aβ [73, 74] and bind to Aβ deposits in human AD brain [75]
and after peripheral administration in animal models in vivo
[74], they may offer a more native therapeutical approach to
combat towards Aβ. An alternative vaccination strategy also
was described with glatiramer acetate, a weak agonist of auto-
antigens, involving recruitment of BM-derived dendritic cells
and their regulation of Aβ deposition [57, 76].
Findings on certain cell types, receptors, or pharmacolog-
ical treatments associated with Aβ clearance by microglia or
monocytic cells in animal models of AD are represented in
Table 2. Many pharmacological approaches such as galant-
amine [77], valproic acid [78], and cannabinoids [79] have
been shown to enhance phagocytosis and potentially, clear-
ance of Aβ in mouse microglial or monocytic cells in vitro.
Pharmacological approach with curcuminoids also was shown
to result in Aβ clearance by human monocytes obtained from
AD patients [29, 80], suggesting that in vitro models of AD
may be applicable to study monocytic function in AD. Fur-
thermore, therapeutical approaches not directly associated
with Aβ phagocytosis may have unexpected effects on micro-
glial function as reported for galantamine and γ-secretase
inhibitors increasing and inhibiting microglial Aβ phagocy-
tosis, respectively [77, 81].
Conclusions
Transgenic AD mouse models have revolutionized the re-
search of mechanisms leading to Aβ clearance by cells of
myeloid origin. Several in vitro and ex vivo methods assess-
ing the phagocytic capacity of microglia and BM-derived
monocytic cells have been developed. Increasing knowl-
edge of the heterogeneity of microglial function in AD has
changed the course of research to not only dampen micro-
glial reactivity but also to modulate their activation proper-
ties. Pinpointing such events leading to reduction in brain
toxic Aβ levels offers an attractive tool for combating this
devastating disease.
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